Dimethyl Fumarate Exerts Selective Effects on Key B Cell Subsets and IgG Levels Which May Contribute to its Therapeutic Benefit in MS While Maintaining Protective Humoral Immunity (P2.2-069)
Amit Bar‐Or(University of Pennsylvania), Sami Fam(Biogen (United States)), Yang Mao‐Draayer(University of Michigan), Fabrizio Giuliani(University of Alberta), Devangi Mehta(Biogen (United States)), Chongshu Chen(Alnylam Pharmaceuticals (United States)), Becky Parks(University of Vermont), Scott S. Zamvil(University of California, San Francisco)
Cited by 0
Related Papers
Ocrelizumab versus Interferon Beta-1a in Relapsing Multiple Sclerosis
|New England Journal of Medicine|2016|2k
Ocrelizumab versus Placebo in Primary Progressive Multiple Sclerosis
|New England Journal of Medicine|2016|1.9k
Human TH17 lymphocytes promote blood-brain barrier disruption and central nervous system inflammation
|Nature Medicine|2007|1.8k
Multiple sclerosis
|Nature Reviews Disease Primers|2018|1.4k